Analysis of Lead in Soils Adjacent to an Interstate Highway in Tampa, Florida

In order to assess the amount and distribution of lead pollution in soils adjacent to a major interstate highway serving the city of Tampa, Florida, a total of 224 samples were collected from 32 transects perpendicular to the roadway. The lead content was measured using atomic absorption spectrophotometry. The highest levels of lead were found at distances of 81, 243, and 729 cm from the road. The results show that there is a weak negative correlation between soil lead and the distance from the roadside, as well as with traffic density. The weakness of the relationship is a result of confounding variables such as turbulence and other microclimatic factors, downslope movement of soils overtime, and human action such as construction and highway landscaping. Nevertheless, over one-third of the samples collected in the study area contain more than 500 μg g−1 lead, levels considered to be hazardous by the United States Centers for Disease Control and the Environmental Protection Agency

Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study)

BACKGROUND: Treatment with angiotensin-converting-enzyme (ACE) inhibitors reduces the rate of cardiovascular events among patients with left-ventricular dysfunction and those at high risk of such events. We assessed whether the ACE inhibitor perindopril reduced cardiovascular risk in a low-risk population with stable coronary heart disease and no apparent heart failure. METHODS: We recruited patients from October, 1997, to June, 2000. 13655 patients were registered with previous myocardial infarction (64%), angiographic evidence of coronary artery disease (61%), coronary revascularisation (55%), or a positive stress test only (5%). After a run-in period of 4 weeks, in which all patients received perindopril, 12218 patients were randomly assigned perindopril 8 mg once daily (n=6110), or matching placebo (n=6108). The mean follow-up was 4.2 years, and the primary endpoint was cardiovascular death, myocardial infarction, or cardiac arrest. Analysis was by intention to treat. FINDINGS: Mean age of patients was 60 years (SD 9), 85% were male, 92% were taking platelet inhibitors, 62% beta blockers, and 58% lipid-lowering therapy. 603 (10%) placebo and 488 (8%) perindopril patients experienced the primary endpoint, which yields a 20% relative risk reduction (95% CI 9-29, p=0.0003) with perindopril. These benefits were consistent in all predefined subgroups and secondary endpoints. Perindopril was well tolerated. INTERPRETATION: Among patients with stable coronary heart disease without apparent heart failure, perindopril can significantly improve outcome. About 50 patients need to be treated for a period of 4 years to prevent one major cardiovascular event. Treatment with perindopril, on top of other preventive medications, should be considered in all patients with coronary heart disease